title: Effect of mitomycin-C on posterior capsule opacification in rabbit eyes.
abstract: OBJECTIVE
  To determine whether mitomycin-C can inhibit posterior capsule opacification (PCO) without causing ocular toxicity.
  
  
  METHODS
  Yonsei Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea.
  
  
  METHODS
  Mitomycin-C dissolved in sodium hyaluronate (0.2 cc of 0.2 mg/mL) was injected into the empty capsular bag for 3 minutes after endocapsular phacoemulsification in rabbit eyes. Three months after surgery, the obstruction rate of visible light caused by PCO was measured using an optical power meter.
  
  
  RESULTS
  The mean obstruction rate of visible light was 81.0% +/- 8.3% (SD) in the control group in which sodium hyaluronate without mitomycin-C was used, 30.5% +/- 10.1% in the group in which mitomycin-C was dissolved in sodium hyaluronate, and 71.9% +/- 6.8% in the group in which mitomycin-C was dissolved in a balanced salt solution. Statistically significant differences were found among all 3 groups.
  
  
  CONCLUSIONS
  Our results suggest that the application of mitomycin-C dissolved in sodium hyaluronate effectively reduces PCO in rabbit eyes.
authors.affiliation: Yonsei Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, South Korea. hschung@iupui.edu
authors.forename: H S
authors.initials: HS
authors.lastname: Chung
authors.forename: S J
authors.initials: SJ
authors.lastname: Lim
authors.forename: H B
authors.initials: HB
authors.lastname: Kim
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D002386:Cataract / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D002455:Cell Division / Q000187:drug effects; D004338:Drug Combinations; D006820:Hyaluronic Acid / Q000008:administration & dosage; D007267:Injections; D007903:Lens Capsule, Crystalline / Q000187:drug effects / Q000473:pathology; D016685:Mitomycin / Q000008:administration & dosage*; D018918:Phacoemulsification / Q000009:adverse effects; D011817:Rabbits
chemical_list: D000276:Adjuvants, Immunologic; D000903:Antibiotics, Antineoplastic; D004338:Drug Combinations; D016685:Mitomycin; D006820:Hyaluronic Acid